TWI772488B - 新穎DLBCL病患次族群之歐比托珠單抗(obinutuzumab)治療 - Google Patents

新穎DLBCL病患次族群之歐比托珠單抗(obinutuzumab)治療 Download PDF

Info

Publication number
TWI772488B
TWI772488B TW107127631A TW107127631A TWI772488B TW I772488 B TWI772488 B TW I772488B TW 107127631 A TW107127631 A TW 107127631A TW 107127631 A TW107127631 A TW 107127631A TW I772488 B TWI772488 B TW I772488B
Authority
TW
Taiwan
Prior art keywords
patient
dlbcl
patients
chop
antibody
Prior art date
Application number
TW107127631A
Other languages
English (en)
Chinese (zh)
Other versions
TW201910353A (zh
Inventor
米蓋爾 塞爾 奧斯特加
Original Assignee
瑞士商赫孚孟拉羅股份公司
美商納諾史特林科技公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 瑞士商赫孚孟拉羅股份公司, 美商納諾史特林科技公司 filed Critical 瑞士商赫孚孟拉羅股份公司
Publication of TW201910353A publication Critical patent/TW201910353A/zh
Application granted granted Critical
Publication of TWI772488B publication Critical patent/TWI772488B/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW107127631A 2017-08-08 2018-08-08 新穎DLBCL病患次族群之歐比托珠單抗(obinutuzumab)治療 TWI772488B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762542489P 2017-08-08 2017-08-08
US62/542,489 2017-08-08

Publications (2)

Publication Number Publication Date
TW201910353A TW201910353A (zh) 2019-03-16
TWI772488B true TWI772488B (zh) 2022-08-01

Family

ID=63209389

Family Applications (1)

Application Number Title Priority Date Filing Date
TW107127631A TWI772488B (zh) 2017-08-08 2018-08-08 新穎DLBCL病患次族群之歐比托珠單抗(obinutuzumab)治療

Country Status (20)

Country Link
US (2) US11597772B2 (OSRAM)
EP (1) EP3665196B1 (OSRAM)
JP (2) JP7418322B2 (OSRAM)
KR (1) KR102799421B1 (OSRAM)
CN (2) CN111032692A (OSRAM)
AU (1) AU2018314765C1 (OSRAM)
CA (1) CA3071618A1 (OSRAM)
CR (1) CR20200061A (OSRAM)
ES (1) ES2933256T3 (OSRAM)
IL (1) IL272418B2 (OSRAM)
MA (1) MA49830A (OSRAM)
MX (1) MX2020001493A (OSRAM)
MY (1) MY202382A (OSRAM)
PE (1) PE20200738A1 (OSRAM)
PL (1) PL3665196T3 (OSRAM)
SG (1) SG11202000985XA (OSRAM)
TW (1) TWI772488B (OSRAM)
UA (1) UA126204C2 (OSRAM)
WO (1) WO2019030260A1 (OSRAM)
ZA (1) ZA202000680B (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12227567B2 (en) 2017-07-25 2025-02-18 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
MX2020001493A (es) * 2017-08-08 2020-03-24 Hoffmann La Roche Tratamiento con obinutuzumab nuevo subgrupo de pacientes con nuevo linfoma de celulas b grandes difusas (dlbcl).
WO2020092427A1 (en) * 2018-10-29 2020-05-07 Tigatx, Inc. COMPOSITIONS AND METHODS COMPRISING IgA ANTIBODY CONSTRUCTS
CN116063520A (zh) 2019-01-30 2023-05-05 真和制药有限公司 抗gal3抗体及其用途
CN116157151A (zh) 2020-05-26 2023-05-23 真和制药有限公司 通过阻断半乳凝素-3治疗炎性疾病的方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2957177B2 (ja) 1986-03-20 1999-10-04 日本電気株式会社 マイクロコンピユータ
DE69303494T2 (de) 1992-11-13 1997-01-16 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
JP3919235B2 (ja) 1997-06-13 2007-05-23 ジェネンテク，インコーポレイテッド 抗体製剤
BRPI0416262B1 (pt) 2003-11-05 2022-04-12 Roche Glycart Ag Anticorpo anti-cd20 humano tipo ii humanizado, seu método de produção, seus usos, bem como polinucleotídeo isolado, vetor de expressão e composição farmacêutica
GB0718684D0 (en) * 2007-09-24 2007-10-31 Roche Products Ltd Treatment method
US20130195843A1 (en) * 2010-06-23 2013-08-01 British Columbia Cancer Agency Branch Biomarkers for Non-Hodgkin Lymphomas and Uses Thereof
DE102013222576A1 (de) 2013-11-06 2015-05-07 BSH Bosch und Siemens Hausgeräte GmbH Haushaltsgerät
AU2014346788B8 (en) * 2013-11-06 2021-01-28 Arizona Board Of Regents On Behalf Of The Unviersity Of Arizona Method for subtyping lymphoma types by means of expression profiling
WO2015067586A2 (en) 2013-11-07 2015-05-14 F. Hoffmann-La Roche Ag Combination therapy of an anti cd20 antibody with a btk inhibitor
EP3122900A1 (en) * 2014-03-24 2017-02-01 F. Hoffmann-La Roche AG Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
US20160137727A1 (en) * 2014-09-15 2016-05-19 Genentech, Inc. Antibody formulations
EP3262071B8 (en) * 2014-09-23 2022-05-18 F. Hoffmann-La Roche AG Method of using anti-cd79b immunoconjugates
CA2986437A1 (en) * 2015-06-08 2016-12-15 Debiopharm International, S.A. Anti-cd37 immunoconjugate and anti-cd20 antibody combinations
MX2017016651A (es) 2015-06-24 2018-05-14 Hoffmann La Roche Anticuerpos contra csf-1r humano para su uso en la induccion de linfocitosis en linfomas o leucemias.
EP3178848A1 (en) * 2015-12-09 2017-06-14 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
KR102850929B1 (ko) 2015-12-09 2025-08-27 에프. 호프만-라 로슈 아게 항-약물 항체의 형성을 감소시키기 위한 ii형 항-cd20 항체
MX2020001493A (es) * 2017-08-08 2020-03-24 Hoffmann La Roche Tratamiento con obinutuzumab nuevo subgrupo de pacientes con nuevo linfoma de celulas b grandes difusas (dlbcl).

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
期刊 Lenz G et al., "Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways" Proc Natl Acad Sci U S A. 105(36),The National Academy of Sciences of the USA2008 Sep 9; 13520-5 *
期刊 Umberto Vitolo et al., "Obinutuzumab or Rituximab Plus CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma: Final Results from an Open-Label, Randomized Phase 3 Study (GOYA)" Blood, 128(22),the American Society of Hematology 2016, 470.; *

Also Published As

Publication number Publication date
MY202382A (en) 2024-04-24
US20230348611A1 (en) 2023-11-02
TW202323297A (zh) 2023-06-16
PE20200738A1 (es) 2020-07-23
US20200317800A1 (en) 2020-10-08
ZA202000680B (en) 2024-09-25
EP3665196B1 (en) 2022-10-19
ES2933256T3 (es) 2023-02-03
JP7418322B2 (ja) 2024-01-19
CR20200061A (es) 2020-05-23
JP2023179425A (ja) 2023-12-19
CA3071618A1 (en) 2019-02-14
AU2018314765C1 (en) 2025-11-20
MA49830A (fr) 2021-03-31
AU2018314765A1 (en) 2020-01-30
TW201910353A (zh) 2019-03-16
UA126204C2 (uk) 2022-08-31
JP2020530002A (ja) 2020-10-15
AU2018314765B2 (en) 2025-03-20
KR102799421B1 (ko) 2025-04-30
MX2020001493A (es) 2020-03-24
IL272418B1 (en) 2024-05-01
NZ761111A (en) 2024-05-31
IL272418B2 (en) 2024-09-01
CN119798437A (zh) 2025-04-11
CN111032692A (zh) 2020-04-17
WO2019030260A1 (en) 2019-02-14
EP3665196A1 (en) 2020-06-17
US11597772B2 (en) 2023-03-07
SG11202000985XA (en) 2020-02-27
PL3665196T3 (pl) 2023-01-23
IL272418A (en) 2020-03-31
KR20200035441A (ko) 2020-04-03

Similar Documents

Publication Publication Date Title
JP7771138B2 (ja) 腫瘍処置法
US20230348611A1 (en) Obinutuzumab treatment of a dlbcl patient subgroup
EP3886875B1 (en) Methods for treatment using adoptive cell therapy
US20240190963A1 (en) Methods of treating tumor
CN104427992B (zh) 生物标志物及使用溶瘤病毒和免疫调节剂的组合疗法
US20220025049A1 (en) Treatment of hodgkin lymphoma using an anti-pd-1 antibody
US20160347836A1 (en) Treatment of hodgkin's lymphoma using an anti-pd-1 antibody
TW201900193A (zh) 用於癌症治療之生物標記物
US20210380693A1 (en) Methods of treating tumor
KR20230104233A (ko) 소세포 폐암의 분류 및 치료를 위한 방법 및 시스템
HK40027710A (en) Obinutuzumab treatment of a dlbcl patient subgroup
HK1208349B (zh) 生物标志物及使用溶瘤病毒和免疫调节剂的组合疗法